First Pacific Financial Has $256,000 Stock Position in Johnson & Johnson (NYSE:JNJ)

First Pacific Financial lifted its stake in Johnson & Johnson (NYSE:JNJ) by 16.3% during the 1st quarter, HoldingsChannel reports. The fund owned 1,544 shares of the company’s stock after buying an additional 216 shares during the period. First Pacific Financial’s holdings in Johnson & Johnson were worth $256,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in Johnson & Johnson by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company’s stock worth $33,666,460,000 after purchasing an additional 1,772,706 shares during the period. Geode Capital Management LLC raised its stake in Johnson & Johnson by 2.8% during the fourth quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company’s stock worth $8,321,881,000 after acquiring an additional 1,561,036 shares in the last quarter. Northern Trust Corp raised its stake in Johnson & Johnson by 12.3% during the fourth quarter. Northern Trust Corp now owns 30,813,175 shares of the company’s stock worth $4,456,201,000 after acquiring an additional 3,363,235 shares in the last quarter. Norges Bank acquired a new position in Johnson & Johnson during the fourth quarter worth $4,390,037,000. Finally, Wellington Management Group LLP raised its stake in Johnson & Johnson by 1.8% during the fourth quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company’s stock worth $3,522,447,000 after acquiring an additional 431,205 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $152.25 on Friday. The business’s 50-day simple moving average is $153.85 and its 200 day simple moving average is $153.69. The stock has a market cap of $366.33 billion, a price-to-earnings ratio of 16.94, a P/E/G ratio of 2.31 and a beta of 0.42. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to analysts’ expectations of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. As a group, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.42%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s dividend payout ratio (DPR) is 57.84%.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Leerink Partnrs lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Raymond James Financial dropped their price objective on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research note on Monday, April 14th. The Goldman Sachs Group upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Barclays dropped their price objective on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a research note on Thursday, April 17th. Finally, Bank of America lowered their target price on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a research note on Thursday, April 10th. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.